Last €0.01 EUR
Change Today +0.002 / 20.00%
Volume 0.0
DU8 On Other Exchanges
As of 2:13 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

genetic technologies ltd (DU8) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/7/13 - €0.07
52 Week Low
09/17/14 - €0.0090
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENETIC TECHNOLOGIES LTD (DU8)

genetic technologies ltd (DU8) Related Bloomberg News

View More Bloomberg News

genetic technologies ltd (DU8) Related Businessweek News

No Related Businessweek News Found

genetic technologies ltd (DU8) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and gene testing for gene related disorders. The company also provides DNA based tests comprising antenatal DNA testing, deceased estate DNA testing, DNA profiling, grandparent DNA testing, immigration DNA testing, legal paternity DNA testing, non-legal paternity DNA testing, sibling DNA testing, twins DNA testing, and Y-chromosome DNA testing services to determine parentage or relatedness. In addition, it offers animals’ tests consisting of disease testing, breed identification, coat color, and animal forensic DNA testing. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Founded in 1987

genetic technologies ltd (DU8) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$223.1K
Senior Vice President Sales & Marketing - Phe...
Total Annual Compensation: A$222.0K
Scientific Director
Total Annual Compensation: A$114.1K
Compensation as of Fiscal Year 2013.

genetic technologies ltd (DU8) Key Developments

Genetic Technologies Limited Plans for the Restructure and Realignment of Group Activities

Genetic Technologies Limited announced that it plans for the restructure and realignment of group activities. These changes will enable the company to focus its strategy on the US molecular diagnostics market and commercialisation of the company's lead breast cancer risk test BREVAGenTM. The restructure and realignment of group activities follows a recent review of operations by the company aimed at supporting the company's US MDx strategy. The core plans approved by the board include: the sale /divestment of non-core assets; the realignment of internal cost structures through a disciplined approach to cost management and capital allocation being driven by the recently appointed CFO; a board restructure, including the appointment of new directors, to support and enhance company's focus on the US MDx market; and a proposed company name change to represent a MDx focus. The plans being implemented are targeted for completion over the next quarter, and are expected to provide investors with a focused MDx company and refined US commercialisation strategy for BREVAGen, with a significantly reduced operating cost base.

Genetic Technologies Limited Reports Consolidated Earnings Results for the Year Ended June 30, 2014

Genetic Technologies Limited reported consolidated earnings results for the year ended June 30, 2014. For the year, the company reported loss from continuing operations before income tax expense of $10,134,469, loss attributable to owners of the company of $10,125,197 or 1.76 cents per basic and diluted share on revenue from continuing operations ­ genetic testing services of $4,564,280 against loss from continuing operations before income tax expense of $9,349,483, loss of $9,349,483, loss attributable to owners of the company of $9,298,367 or 1.97 cents per basic and diluted share on revenue from continuing operations ­ genetic testing services of $3,377,183 for the same period a year ago. Net cash flows used in operating activities of $10,987,088 against $7,516,779 for the same period a year ago. Purchases of plant and equipment were $47,917 against $53,611 for the same period a year ago.

Genetic Technologies Limited Appoints Eutillio Buccilli as Chief Financial Officer, Effective 2 June 2014

Genetic Technologies Limited announced the appointment of Mr. Eutillio Buccilli to the role of Chief Financial Officer, effective 2 June 2014. Mr. Buccilli joins Genetic Technologies after more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the USA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DU8:GR €0.01 EUR +0.002

DU8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $58.25 USD -0.15
Bristol-Myers Squibb Co $51.51 USD +0.39
Pfizer Inc $30.40 USD -0.18
Sonic Healthcare Ltd A$17.48 AUD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation DU8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at